Clinical Trials
44 trialsA Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Sun Yat-sen University
FAD-HCC-001
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
First Affiliated Hospital of Chongqing Medical University
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Jiangsu HengRui Medicine Co., Ltd.
Cocktail-001
Shanghai Zhongshan Hospital
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
ICT-HCC
Nanjing Tianyinshan Hospital
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
CCGLC-001
Tongji Hospital
Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
Shanghai Zhongshan Hospital
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
Zhujiang Hospital
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma
Fujian Cancer Hospital
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
Qilu Hospital of Shandong University
HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study
Sun Yat-sen University
CCGLC-008
Tongji Hospital
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
Fujian Medical University
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
Guangxi Medical University
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Jiangsu HengRui Medicine Co., Ltd.
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
Zhongda Hospital
CAPT
Zhejiang University
Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC
Nanfang Hospital, Southern Medical University
C-couple
Sun Yat-sen University
IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC
Third Affiliated Hospital, Sun Yat-Sen University
A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma
China Three Gorges University, Yichang, China
Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
Zhejiang University
SHR-1210
Shanghai Zhongshan Hospital
HZ-T-PD1-APA
Harbin Medical University
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
Shanghai Zhongshan Hospital
The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus
Guangxi Medical University
The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients
Guangxi Medical University
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
HCC
Tianjin Medical University Cancer Institute and Hospital
Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection
Shanghai Zhongshan Hospital
Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma
First Affiliated Hospital of Guangxi Medical University
Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma
Jiangsu Cancer Institute & Hospital
HCC
Tianjin Medical University Cancer Institute and Hospital
A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure
The First Affiliated Hospital of Zhengzhou University
A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
Peking University Cancer Hospital & Institute
Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
Zhejiang Cancer Hospital